Bacterial coinfections in COVID-19: an underestimated adversary

Area of Science:

• Infectious Diseases
• Microbiology
• Critical Care Medicine

Background:

• Secondary bacterial infections are a recognized complication in COVID-19 patients.
• While less frequent than in prior influenza pandemics, specific bacterial species like Mycoplasma pneumoniae and Staphylococcus aureus are commonly isolated.
• Coinfections with Mycobacterium tuberculosis are also documented.

Purpose of the Study:

• To review the current literature on secondary bacterial infections in COVID-19 patients.
• To highlight the increased risk of bacterial coinfections in intensive care unit (ICU) settings.
• To emphasize the need for revised antibiotic prescription strategies and antimicrobial stewardship.

Main Methods:

• Literature review of current scientific publications.
• Analysis of reported bacterial species involved in COVID-19 coinfections.
• Assessment of coinfection rates in relation to patient location (e.g., ICU).

Main Results:

• Commonly isolated bacteria include Mycoplasma pneumoniae, Staphylococcus aureus, Legionella pneumophila, Streptococcus pneumoniae, Haemophilus, and Klebsiella spp.
• Bacterial coinfection rates are significantly higher in ICU-admitted patients.
• Superinfections with nosocomial antibiotic-resistant bacteria are a growing concern.

Conclusions:

• The findings underscore the importance of judicious antibiotic use in COVID-19 management.
• There is an urgent need to move away from empiric broad-spectrum antibiotic prescriptions.
• Adherence to evidence-based practices and antimicrobial stewardship principles is essential to mitigate resistance.